Comparison of the predictive value of area under the curve versus maximum serum concentration of intravenous tobramycin in cystic fibrosis patients treated for an acute pulmonary exacerbation

Pulmonary Fibrosis

Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis

Chest.

Hong LT, Liou TG, Deka R, King JB, Stevens V, Young DC

doi: 10.1016/j.chest.2018.06.002.

RECOMMENDED

Pulmonary Fibrosis

Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis

Ann Am Thorac Soc.

Somayaji R, Russell R, Cogen JD, Goss CH, Nick SE, Saavedra MT, Taylor-Cousar JL, Nick JA, Nichols DP

doi: 10.1513/AnnalsATS.

COPD

Population exacerbation incidence contains predictive information of acute exacerbations in patients with chronic obstructive pulmonary disease in telecare

Int J Med Inform.

Kronborg T, Mark L, Cichosz SL, Secher PH, Hejlesen O

doi: 10.1016/j.ijmedinf.

RECOMMENDED

Pulmonary Fibrosis

Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis

Cochrane Database Syst Rev.

Smith S, Rowbotham NJ, Charbek E

doi: 10.1002/14651858.

COMMENTED

Pulmonary Fibrosis

Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials

Lancet Respir Med.

Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C, Jia G, Peng K, Ray JM, Ley B, Wolters PJ, Collard HR, Arron JR

doi: 10.1016/

Pulmonary Fibrosis

Safety of intravenous tobramycin in combination with a variety of anti-pseudomonal antibiotics in children with cystic fibrosis

SAGE Open Med.

Deschamp AR, Pettit RS, Donaldson JA, Slaven JE, Davis SD

doi: 10.1177/2050312117736694.

RECOMMENDED

Pulmonary Fibrosis

Duration of intravenous antibiotic treatment for acute exacerbations of cystic fibrosis: A systematic review: Duration of treatment for acute exacerbations of cystic fibrosis

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

J Cyst Fibros

Nicholson TT, Smith A, McKone EF, Gallagher CG

doi: 10.1016/j.jcf.2021.08.017

Pulmonary Fibrosis

Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection

Ther Adv Respir Dis.

Greenwood J, Schwarz C, Sommerwerck U, Nash EF, Tamm M, Cao W, Mastoridis P, Debonnett L, Hamed K

doi: 10.1177/

RECOMMENDED

Pulmonary Fibrosis

BAL inflammatory markers can predict pulmonary exacerbations in children with cystic fibrosis

★ 2 Recommended by Dr Martin Frey, Faculty Member

Chest.

Ishak A, Stick SM, Turkovic L, Ranganathan SC, King L, Harrison J, Sly PD, Caudri D, Schultz A, AREST CF.

doi: 10.1016/j.chest.2020.06.044.

Related content

Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis

Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis

Population exacerbation incidence contains predictive information of acute exacerbations in patients with chronic obstructive pulmonary disease in telecare

Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis

Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials

Safety of intravenous tobramycin in combination with a variety of anti-pseudomonal antibiotics in children with cystic fibrosis

Duration of intravenous antibiotic treatment for acute exacerbations of cystic fibrosis: A systematic review: Duration of treatment for acute exacerbations of cystic fibrosis

Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection

BAL inflammatory markers can predict pulmonary exacerbations in children with cystic fibrosis